Wake Forest Atrium HeartShare Clinical Center

维克森林中庭 HeartShare 临床中心

基本信息

项目摘要

Project Summary Heart Failure with Preserved Ejection Fraction (HFpEF) is the most common form of HF in the US and is associated with high morbidity and mortality. However, its pathophysiology is incompletely understood, and most trials have been neutral such that few evidence-based treatments exist. In response, NIH convened 2 workshops co-led by Dr. Kitzman (PI). The highest priority research recommendation was a coordinated effort to create a large cohort of HFpEF patients and controls and perform comprehensive, deep phenotyping. This became the basis for HeartShare, whose ultimate goals are to discover novel HFpEF mechanisms, subtypes, and therapeutic targets. Our Wake Forest - Atrium HFpEF team is highly qualified to serve as a Clinical Center and make robust, over-arching contributions to HeartShare. Dr. Kitzman is internationally recognized as a thought-leader in HFpEF with a sustained track record of developing novel concepts regarding HFpEF pathogenesis, mechanisms, and outcomes and designing and conducting innovative studies to test them. His team has extensive experience in all key aspects of the HeartShare program, particularly in recruiting, retaining, and phenotyping diverse populations of HFpEF patients and controls, often significantly exceeding goals for racial and gender diversity. Our institutions have ~15,000 HFpEF clinical visits annually. In all, our team has led or helped lead recruitment and phenotyping for 69 studies, mostly NIH-sponsored, with 15,354 participants, demonstrating our ability to fulfill HeartShare recruitment and phenotyping goals. Data from these studies will be contributed to the Cohort phase of HeartShare. We will make robust contributions to HeartShare by achieving 4 Specific Aims: Aim 1) Provide ‘thought leadership’ in collaboration with the HeartShare Steering Committee; Aim 2) Contribute data, images, and stored specimens cohort phase of HeartShare from our numerous studies of HFpEF and controls, and identify and phenotype HFpEF patients and controls from the electronic health record using robust bioinformatics tools; Aim 3) Recruit, consent, enroll and follow at least 250 HFpEF patients plus controls (type and number to be determined by consensus); Aim 4) Conduct state-of- the-art deep phenotyping exams using a collaboratively determined protocol. Our phenotyping proposal is highly innovative, with advanced echo-Doppler and cardiac magnetic resonance imaging, CPET, physical activity monitoring, remote and artificial intelligence electrocardiography, sampling of skeletal muscle, adipose, blood, and microbiome, and mitochondrial energetics, and brain structure/function. Our diverse, cross- disciplinary team has the full range of complementary expertise and access to the robust resources of two large, closely affiliated health systems to ensure fulfillment of all HeartShare’s goals. We will help accelerate and optimize the program’s success with our insight, creativity, and sustained track record of collaboration, innovation, and dissemination.
项目摘要 射血分数保留性心力衰竭(HFpEF)是美国最常见的HF形式, 与高发病率和死亡率相关。然而,其病理生理学尚未完全了解, 大多数试验都是中立的,因此几乎没有基于证据的治疗方法。作为回应,NIH召集了2 由Kitzman博士(PI)共同领导的研讨会。最高优先级的研究建议是协调努力 建立一个HFpEF患者和对照的大型队列,并进行全面、深入的表型分析。这 成为HeartShare的基础,其最终目标是发现新的HFpEF机制,亚型, 和治疗靶点。我们的维克森林- Atrium HFpEF团队具备作为临床中心的高素质 并为HeartShare提供强大的超额捐款。Kitzman博士是国际公认的 HFpEF的思想领袖,在开发HFpEF新概念方面有着持续的记录 发病机制,机制和结果,并设计和进行创新的研究来测试它们。他 团队在HeartShare计划的所有关键方面都有丰富的经验,特别是在招聘方面, 保留HFpEF患者和对照的不同人群,并对其进行表型分型,通常显著超过 种族和性别多样性。我们的机构每年约有15,000次HFpEF临床访视。总之,我们的 该团队已经领导或帮助领导了69项研究的招募和表型分析,其中大部分是NIH赞助的, 参与者,证明我们有能力实现HeartShare招募和表型分析目标。数据从这些 研究将被贡献给HeartShare的队列阶段。我们将为HeartShare做出巨大贡献 通过实现4个具体目标:目标1)与HeartShare Steering合作,提供“思想领导力” 委员会;目标2)从我们的HeartShare贡献数据,图像和储存的样本队列阶段 对HFpEF和对照的大量研究,并从HFpEF患者和对照中鉴定和表型。 使用强大的生物信息学工具的电子健康记录;目标3)招募、同意、登记和随访至少 250例HFpEF患者加对照组(类型和数量由共识确定);目的4) 使用协作确定的协议进行最先进的深度表型检查。我们的表型分析方案是 具有高度创新性,先进的回波多普勒和心脏磁共振成像,CPET,物理 活动监测,远程和人工智能心电图,骨骼肌,脂肪, 血液、微生物组、线粒体能量学和大脑结构/功能。我们多样化的,交叉的- 学科团队拥有全方位的互补专业知识,并可获得两个强大的资源 大型的、紧密联系的卫生系统,以确保实现所有HeartShare的目标。我们将帮助加快 并利用我们的洞察力、创造力和持续的合作记录来优化项目的成功, 创新和传播。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DALANE W KITZMAN其他文献

DALANE W KITZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DALANE W KITZMAN', 18)}}的其他基金

Repurposing of Metormin for Older Patients with HFpEF
老年 HFpEF 患者重新使用美托明
  • 批准号:
    10434271
  • 财政年份:
    2022
  • 资助金额:
    $ 27.47万
  • 项目类别:
Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial
老年急性 HFpEF 患者的身体康复 - REHAB-HFpEF 试验
  • 批准号:
    10683332
  • 财政年份:
    2022
  • 资助金额:
    $ 27.47万
  • 项目类别:
Repurposing of Metormin for Older Patients with HFpEF
老年 HFpEF 患者重新使用美托明
  • 批准号:
    10672897
  • 财政年份:
    2022
  • 资助金额:
    $ 27.47万
  • 项目类别:
Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial
老年急性 HFpEF 患者的身体康复 - REHAB-HFpEF 试验
  • 批准号:
    10501900
  • 财政年份:
    2022
  • 资助金额:
    $ 27.47万
  • 项目类别:
Wake Forest Atrium HeartShare Clinical Center
维克森林中庭 HeartShare 临床中心
  • 批准号:
    10483210
  • 财政年份:
    2021
  • 资助金额:
    $ 27.47万
  • 项目类别:
Wake Forest Atrium HeartShare Clinical Center
维克森林中庭 HeartShare 临床中心
  • 批准号:
    10678972
  • 财政年份:
    2021
  • 资助金额:
    $ 27.47万
  • 项目类别:
Improving the usage and impact of the Integrated Aging Studies Databank and Registry
改善综合老龄化研究数据库和登记处的使用和影响
  • 批准号:
    10408207
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:
Coordinating Center of the Claude D. Pepper Older Americans Independence Centers
克劳德·D·佩珀美国老年人独立中心协调中心
  • 批准号:
    10163762
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:
Coordinating Center of the Claude D. Pepper Older Americans Independence Centers
克劳德·D·佩珀美国老年人独立中心协调中心
  • 批准号:
    10449365
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:
Pepper OAIC Coordinating Center
佩珀 OAIC 协调中心
  • 批准号:
    10621613
  • 财政年份:
    2018
  • 资助金额:
    $ 27.47万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.47万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了